NeuroVive conducts a directed new share issue of SEK 5.3 Million
Lund, Sweden, 3 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), a leading company in mitochondrial medicine, announced today that the company is conducting a directed new issue of shares, which is expected to add close to SEK 5.3 million to NeuroVive. Proceeds from the new share issue will be used primarily for continued clinical development of KL1333 and NeuroSTAT.NeuroVive's Board of Directors has decided to conduct a private placement of approximately SEK 5.3 million to Floyd Associates Europe Limited. The new issue of shares with a deviation from